U.S. equities climbed higher on Monday in a continuation of the easy, low volatility conditions that have dominated over the past three months. Large-cap stocks, as measured by the S&P 500, closed above the 2,400 level for the first time, bagging another high.
In the end, the Dow Jones Industrial Average gained 0.4%, the S&P wafted up 0.5%, the Nasdaq Composite added 0.5%....More>>>
San Francisco, California-based Twitter Inc (NYSE:TWTR)hasn’t had a great run this year, and things don’t seem to be getting any better lately. On 9th November, Twitter COO, Adam Bain, announced his departure from the company after a 6 year stint. Less than a month later, on Friday,Twitter’s VP of global online sales, Richard Alfonsi also followed suit, announcing his exit via....More>>>
We have been waiting for an attractive entry point to buy Fabrinet (NYSE:FN) for a couple of months now as the stock has continued its impressive climb upwards. And, after the stock’s recent sell-off over the past few weeks, we believe that now is a great time to buy.
Click to enlarge
Brief Company Overview
Fabrinet is a high-tech contract manufacturer for some of the....More>>>
Crude oil prices are still below the $50 mark this week, but we have some good news for investors…
Our bold oil price prediction shows double-digit gains for the price of oil by the end of 2016.
Money Morning Global Energy Strategist Dr. Kent Moors says oil prices will climb significantly by the end of 2016 and into 2017. Moors is a 40-year veteran in the oil markets, and....More>>>
” Even as I approach the gambling hall, as soon as I hear, two rooms away, the jingle of money poured out on the table, I almost go into convulsions.” /Fyodor Dostoevsky
The newly legislated entry into the global gaming market by Japan has raised prospects of a $30 billion market forming within the first five years of operation. As the implications of this game changing development....More>>>
It would be fair to say biotech has had an interesting time of it over the course of the past 15 months. Except, of course, that biotech always has an interesting time of it. The go big or go home sector of the market attracts speculators, scientists, and unsavory characters, but also attracts people hoping for critical improvements to their healthcare options.
With a lot of sentiment and....More>>>